After the World Health Organisation (WHO) approved Bharat Biotech's Covaxin for emergency use, medical journal Lancet has now stated that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid, as demonstrated by the phase 3 data. The efficacy data demonstrated 70.8 per cent protection against all variants of the SARS-CoV-2 virus.The efficacy rate was confirmed through the evaluation of 130 confirmed cases, with 24 observed in the vaccine group against 106 in the placebo group. As per the phase 3 data, Covaxin was found to be 65.2 per cent effective against the Delta variant, 93.4 per cent effective against severe symptomatic Covid and 63.6 per cent effective against asymptomatic Covid.

After the World Health Organisation (WHO) approved Bharat Biotech's Covaxin for emergency use, medical journal Lancet has now stated that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid, as demonstrated by the phase 3 data. The efficacy data demonstrated 70.8 per cent protection against all variants of the SARS-CoV-2 virus.The efficacy rate was confirmed through the evaluation of 130 confirmed cases, with 24 observed in the vaccine group against 106 in the placebo group. As per the phase 3 data, Covaxin was found to be 65.2 per cent effective against the Delta variant, 93.4 per cent effective against severe symptomatic Covid and 63.6 per cent effective against asymptomatic Covid.